NCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
National Cancer Institute (NCI)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
AbbVie
Milton S. Hershey Medical Center
GlaxoSmithKline
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SUNHO(China)BioPharmaceutical CO., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Fudan University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University